百利天恒：子公司SystImmune与百时美施贵宝合作触发2.5亿美元里程碑付款

Core Insights - SystImmune, a wholly-owned subsidiary of the company, has triggered a milestone event in its collaboration agreement with Bristol-Myers Squibb regarding the BL-B01D1 (EGFR×HER3 dual antibody ADC) project, leading to the receipt of a near-term payment of $250 million [1] Group 1 - The company will receive the payment shortly, with the actual amount subject to bank fees [1] - The collaboration agreement allows the company to potentially receive up to an additional $250 million in near-term payments, as well as up to $7.1 billion in further payments upon achieving specific development, registration, and sales milestones [1]